Hashimoto’s thyroiditis is not a risk factor for thyroid cancer

Main Article Content

Mohsen Eshraghi
Seyed Mojtaba Mousavi


Thyroid carcinoma is the most common endocrine malignancy. Chronic inflammation can be involved in tumorigenesis. It is estimated that more than 20% of all tumors are caused by persistent inflammatory conditions. The objective of the present study was to compare the inflammatory factor level of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and thyroiditis between benign and malignant thyroid nodules.

A cross-sectional study was conducted involving 94 patients (47 patients with benign tumors as controls and 47 patients with malignant tumors as cases). ESR and CRP were measured and analyzed. Mean ESR and CRP in both groups was compared using independent t-test. The chi-square test was used to assess the risk of cancer in patients with Hashimoto’s thyroidits and with significance level at p<0.05.

The mean age of the patients in the benign group was 42.28 ± 13.43 years and in the malignant group 42.20 ± 16.32 (20-85) years, which was not significantly different (p=0.350). Independent t-test results were not significantly different between mean ESR and CRP in both groups (p=0.800 and p=0.993 respectively). Hashimoto’s thyroiditis was not a risk factor for thyroid cancer (OR=1.58; 95% CI:0.63-4.01).

This study demonstrated that Hashimoto’s thyroiditis was not a risk factor for thyroid cancer. Factors such as ESR and CRP are acute phase reactants and their levels increase in cases of acute inflammation, but may not increase significantly in chronic inflammatory conditions and malignancies.

Article Details

How to Cite
Eshraghi, M., & Mousavi, S. M. (2018). Hashimoto’s thyroiditis is not a risk factor for thyroid cancer. Universa Medicina, 37(3), 216–221. https://doi.org/10.18051/UnivMed.2018.v37.216-221
Original Articles


Blomberg M, Feldt-Rasmussen U, Andersen KK, et al. Thyroid cancer in Denmark 1943-2008, before and after iodine supplementation. Int J Cancer 2012;131:2360–6. doi: 10.1002/ijc.27497.

Wang Y, Wang W. Increasing incidence of thyroid cancer in Shanghai, China, 1983-2007. Asia Pac J Public Health 2015;27:N223–9. doi: 10.1177/1010539512436874.

Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006;295:2164–7.

Makazlieva T, Vaskova O, Majstorov V, et al. Demographic and clinical features of thyroid carcinomas in Republic of Macedonia (1999-2010). Macedonian J Med Sci 2017;5:1005-10. DOI: https://doi.org/10.3889/oamjms.2017.183.

Ho AS, Sarti EE, Jain KS, et al. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid 2014;24:832-9. doi: 10.1089/thy.2013.0317.

Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005;115:1068–81.

Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008;54:436–44.

Borrello MG, Alberti L, Ischer A, et al. Induction of proinflammatory program in normal human thyrocytes by the RET/PTC1 onco-gene. Proc Natl Acad Sci 2005;102:14825–30.

Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2011;61:824-33.

Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 2011;48:155-70.

Borrello MG, Alberti L, Ischer A, et al. Induction of proinflammatory program in normal human thyrocytes by the RET/PTC1 onco-gene. Proc Natl Acad Sci 2015;102:14825–30.

Russel JP, Shinoara S, Melillo RM, et al. Tyrosine kinase oncoprotein, RET/PTC3, indices the secretion of myeloid growth and chemotactic factors. Oncogene 2011;22:4569–77.

Hou X, Jiang L, Chen C, et al. Different expression of erythrocyte sedimentation rate and C-reactive protein in papillary thyroid carcinoma and nodular gGoiter. Clin Lab 2015;61:793-9.

Lee JH, Kim Y, Choi JW, et al. The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: a meta-analysis. Europ J Endocrinol 2013;168:343–9. doi: 10.1530/EJE-12-0903.

Rapplinger D, Bargren A, Zhang YW, et al. Is Hashimoto’s tthyroiditis a risk factor for papillary thyroid cancer? J Surg Res 2008;150:49-52.

Jankovic B, Karen T. Le KT, et al. Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab 2013;98:474–82. doi: 10.1210/jc.2012-2978.

Anil C, Goksel S, Gursoy A. Hashimoto's thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid 2010;20:601-6. doi: 10.1089/thy.2009.0450.19.

Baruah MP, Bhattacharya B. Significant role of serum CRP in differentiating inflammatory from non-inflammatory causes of thyrotoxicosis. Indian J Endocrinol Metab 2012;16:976-81. doi: 10.4103/2230-8210.103002.

Kratky J, Jezkova J, Kosak M, et al. Positive antithyroid antibodies and nonsuppressed TSH are Associated with thyroid cancer: a retrospective cross-sectional study. Int J Endocrinol 2018, Article ID 9793850, 6 pages. DOI: https://doi.org/10.1155/2018/9793850.